ANI Pharmaceuticals (ANIP) Projected to Post Earnings on Friday

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) is expected to be posting its Q1 2025 quarterly earnings results before the market opens on Friday, May 9th. Analysts expect ANI Pharmaceuticals to post earnings of $1.37 per share and revenue of $179.75 million for the quarter.

ANI Pharmaceuticals Stock Performance

NASDAQ ANIP opened at $70.69 on Friday. ANI Pharmaceuticals has a 52-week low of $52.50 and a 52-week high of $72.57. The business's 50-day moving average price is $65.24 and its 200 day moving average price is $60.22. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52. The firm has a market cap of $1.54 billion, a P/E ratio of -128.53 and a beta of 0.49.

Insider Activity at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, VP Meredith Cook sold 400 shares of the company's stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $63.33, for a total value of $25,332.00. Following the sale, the vice president now owns 80,545 shares of the company's stock, valued at approximately $5,100,914.85. This represents a 0.49 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Krista Davis sold 1,000 shares of ANI Pharmaceuticals stock in a transaction on Friday, March 7th. The stock was sold at an average price of $60.86, for a total value of $60,860.00. Following the transaction, the senior vice president now directly owns 66,525 shares of the company's stock, valued at $4,048,711.50. This trade represents a 1.48 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 3,200 shares of company stock valued at $197,792 in the last ninety days. Corporate insiders own 11.10% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts have recently commented on ANIP shares. StockNews.com cut ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Thursday, April 24th. Jefferies Financial Group initiated coverage on shares of ANI Pharmaceuticals in a report on Friday, March 14th. They issued a "buy" rating and a $80.00 target price on the stock. Guggenheim reissued a "buy" rating and set a $86.00 price target on shares of ANI Pharmaceuticals in a report on Friday, April 11th. HC Wainwright reaffirmed a "buy" rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a report on Monday, March 17th. Finally, Truist Financial increased their target price on ANI Pharmaceuticals from $62.00 to $65.00 and gave the stock a "hold" rating in a research note on Monday, April 21st. One research analyst has rated the stock with a sell rating, one has issued a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, ANI Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus price target of $80.13.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.